(18)F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results

INTRODUCTION: Tyrosine kinase (TKI) and checkpoint inhibitors (CI) prolonged overall survival in metastatic renal cell carcinoma (mRCC). Early prediction of treatment response is highly desirable for the individualization of patient management and improvement of therapeutic outcome; however, serum b...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittlmeier, L. M., Unterrainer, M., Rodler, S., Todica, A., Albert, N. L., Burgard, C., Cyran, C. C., Kunz, W. G., Ricke, J., Bartenstein, P., Stief, C. G., Ilhan, H., Staehler, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113284/
https://www.ncbi.nlm.nih.gov/pubmed/33369689
http://dx.doi.org/10.1007/s00259-020-05165-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113284/
https://www.ncbi.nlm.nih.gov/pubmed/33369689
http://dx.doi.org/10.1007/s00259-020-05165-3

Ejemplares similares